Compare VanEck Uranium & Nuclear ETF (NLR) vs Novo Nordisk A/S (NVO) Price & Performance

VanEck Uranium & Nuclear ETFTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

VanEck Uranium & Nuclear ETF vs Novo Nordisk A/S — how do they compare? VanEck Uranium & Nuclear ETF trades at $122.23, while Novo Nordisk A/S trades at $44.71 (market cap $200.69B). The key difference: Novo Nordisk A/S pays a 3.98% dividend while VanEck Uranium & Nuclear ETF pays none. Which is the better fit depends on your goals.

	NLR	NVO
Sector	Sector/Thematic	Health
52-Week High	$164.37	$63.98
52-Week Low	$102.70	$35.29
Market Cap	—	$200.69B
Enterprise Value	—	$215.49B
Dividend Yield	—	3.98%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Uranium & Nuclear ETF

No Aura AI signal available yet.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.

NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NLR

View details →

NVO

Canada imposes retaliatory tariffs on $20B of U.S. goods, escalating trade tensions and impacting North American supply chains.Seeking Alpha · 1 day agoNeutral 4-Factor Dividend Growth Strategy slightly outperforms SCHD with 14.89% returns, testing new variants.Seeking Alpha · 3 days agoBullish View details →

About VanEck Uranium & Nuclear ETF

VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.